Abstract
Background After metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD) has recently been redefined again as metabolic dysfunction-associated steatotic liver disease (MASLD). However, the distinctions in characteristics and mortality outcomes between NAFLD, MAFLD, MASLD, and pure-MASLD are still unclear.
Methods We analyzed data from 6,708 participants in the third National Health and Nutrition Examination Surveys 1988-1994 of United States (US) and their linked mortality through 2019. NAFLD, MAFLD, MASLD and pure MASLD were defined based on respective criteria. Survey-weight adjusted multivariable Cox proportional model was used to study the mortality of the four terms.
Results The overall prevalence of NAFLD, MAFLD, MASLD and pure-MASLD was 28.9% (n=1,937), 26.1% (n=1,753), 29.0% (n=1,948), and 26.0% (n=1,741), respectively. For NAFLD, 81.3%, 89.9% and 89.9% fulfilled the criteria for MAFLD, MASLD and pure MASLD. For MAFLD, all were classified into the MASLD, and 89.8% were met the criteria of pure-MASLD. During a median follow-up of 27 years, both individuals with MAFLD and MASLD had higher risk of all-cause mortality (adjusted hazard ratio [aHR]: 1.21, 95% CI 1.09-1.352; and 1.11, 1.00-1.23, respectively). NAFLD and pure-MASLD were not associated with all-cause mortality. All the four terms were associated with increased all-cause mortality in individuals with advanced fibrosis (aHR: 1.66-1.83). Subgroup analyses showed that higher risk of all-cause mortality of NAFLD, MAFLD, MASLD and pure-MASLD were observed in female, age 41-55 years, non-Hispanic white, and never smoking subgroups when focused on moderate-severe hepatic steatosis.
Conclusions In this US population-based study, MASLD could identify more individuals with all-cause mortality risk than MAFLD, meanwhile, NAFLD and pure-MASLD had similar characteristics and mortality outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the first batch of key disciplines on public health in Chongqing, Health Commission of Chongqing, China.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at:https://www.cdc.gov/nchs/nhanes/index.htm.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
